Fig. 1From: The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective studyThe neutrophil-lymphocyte ratio (NLR) of all patients (a), responders whose best response was a complete response (CR), partial response (PR) or stable disease (SD) (b) and non-responders whose best response was progressive disease (PD) (c)Back to article page